STIM241220P2500
- 1.60
- 0.000.00%
Neuronetics Newsroom
Press Release: GREENBROOK TMS REPORTS THIRD QUARTER OPERATIONAL AND FINANCIAL RESULTS
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Newsflash: Neuronetics, Inc. (NASDAQ:STIM) Analysts Have Been Trimming Their Revenue Forecasts
Neuronetics Third Quarter 2024 Earnings: Misses Expectations
Need To Know: The Consensus Just Cut Its Neuronetics, Inc. (NASDAQ:STIM) Estimates For 2025
Greenbrook TMS Acquisition by Neuronetics Approved
Express News | Greenbrook Receives Final Court Approval for Arrangement With Neuronetics
JMP Securities Maintains Neuronetics(STIM.US) With Buy Rating, Maintains Target Price $3
CCORF Maintains Neuronetics(STIM.US) With Buy Rating, Maintains Target Price $3
Neuronetics Buy Rating Supported by Strategic Merger and Cost Synergies Despite Revenue Misses
Neuronetics | 8-K/A: Correction: Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
Neuronetics Faces Nasdaq Delisting Risk: Can It Meet the $1.00 Bid Price Requirement?
Express News | Neuronetics Inc : Piper Sandler Cuts Target Price to $2 From $4
Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript Summary
Press Release: CORRECTION--Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Neuronetics | 8-K: Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
Neuronetics Sees Q3 Revenue Rise Amid Strategic Acquisition